PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today inaugurated its Pall Life Sciences Centre of Excellence in Singapore, the latest addition to the company’s global customer support network. Located in Singapore’s Gemini Science Park II at the heart of Asia’s biosciences industry, Pall’s newest Centre of Excellence provides the most advanced process demonstration, validation support and training capabilities available for a growing base of life sciences customers in the region.
“Pall’s new Singapore Life Sciences Centre of Excellence is representative of our global strategy of investing in high-growth areas where the demand for biotechnology process development and training is acute. It will serve as a central hub for our business and operational activities across the region,” said Yves Baratelli, President, Pall Life Sciences. “This latest Centre of Excellence also reinforces Pall’s commitment to providing high-level technical support for local start-ups as well as multinational customers that do business in the area.”
According to the Singapore Economic Development Board (EDB), seven of the top 10 pharmaceutical companies have located manufacturing facilities in Singapore. Recently, there has been exceptional growth in the area of biologics and vaccines manufacturing, with six new biologics and vaccines plants coming on-stream in the last 36 months. The new Pall facility will cater to this expanding base of manufacturers.
“The Singapore Life Sciences Centre of Excellence consolidates training and technical services, making it unparalleled as a resource for biotechnology companies seeking solutions for their process challenges,” said Eric Garnier, President, Pall Asia. “Biotechnology drugs and biologically derived vaccines are filtration and purification intensive. Pall is singularly well positioned to meet the growing market demand for this expertise.”
The 430-square-meter facility is a showcase for Pall’s full range of life sciences equipment and disposable solutions. These include single-use systems (SUS), depth filter systems, Stax™ systems, tangential flow filtration (TFF) systems, chromatography systems, process monitoring, sterile filters and others. The complex was designed by Pall Scientific and Laboratory Services (SLS) to lead customers through the sequential stages of process flow. It incorporates a series of SLS laboratories dedicated to specific stages of process development, including: disposable media preparation and transfer; upstream processing; cell harvesting and product separation; column packing; disposable media preparation and transfer; purification and polishing; virus reduction and formulation. The complex also offers a simulated cGMP training environment and contains a state-of-the-art seminar and training theater.
“I would like to congratulate Pall on the opening of its new Singapore Life Sciences Centre of Excellence. Leading companies such as Pall play an important role in the development of our biopharmaceutical industry. Pall’s decision to set up the Centre here is an example of how companies are capitalizing on the growth opportunities in Asia through Singapore,” said Mr. Yeoh Keat Chuan, Assistant Managing Director, Singapore Economic Development Board.
For more information about Pall’s new Life Sciences Centre of Excellence, contact asiabiopharm@pall.com or call +6563888688.
About Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.4 billion for fiscal 2010, is an S&P 500 company with more than 10,000 employees serving customers worldwide. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6851596&lang=en